Cometriq (cabozantinib) — Medica
Non-small cell lung cancer with RET gene rearrangement
Initial criteria
- age ≥ 18 years
- recurrent, advanced, or metastatic disease
- RET gene rearrangement-positive tumor
- disease progressed on one of the first-line therapies Gavreto (pralsetinib) or Retevmo (selpercatinib)
Approval duration
1 year